All exploratory efficacy trial results should be disclosed, says IFPMA
This article was originally published in Scrip
Executive Summary
Companies should now disclose information on all confirmatory and exploratory efficacy clinical trials, the International Federation of Pharmaceutical Manufacturers and Associations(IFPMA) has said.